

References

1. Amosova KM, Netiazhenko NV, Mishanych HI. *Ukrainskyi kardiologichnyi zhurnal – Ukrainian Journal of Cardiology* 2010;1:17–23.
2. Amosova KM, Stremeniuk OT, Andrieiev IeV. *Ukrainskyi kardiologichnyi zhurnal – Ukrainian Journal of Cardiology* 2011;8(4):14–20.
3. Barynov EF, Sulaeva ON. *Kardyyolohyia – Cardiology* 2012;12:45–56.
4. Haliavych AS, Valeeva DD, Mynnetdynov RSh. *Kardyyolohyia – Cardiology* 2012;4:20–24.
5. Haliavych AS, Makhyianova EY. *Kardyyolohyia – Cardiology* 2010;7:75–77.
6. Hratsyanskyi NA. *Kardyyolohyia – Cardiology* 2010;6:4–21.
7. Khaspekova SH, Ziuriaev YT, Yakushkyn VV. *Kardyyolohyia – Cardiology* 2011;7:4–7.
8. Abbate R, Cioni G, Ricci I. Thrombosis and acute coronary syndrome. *Thromb Res* 2012;129(3):40–235.
9. Abbracchio MP, Burnstock G, Boeynaems JM. International Union of Pharmacology LVIII: update on the P2Y1 G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. *Pharmacol Rev* 2006;58:281–341.
10. Barn K, Steinhubl SR. A brief review of the past and future of platelet P2Y12 antagonist. *Coron Artery Dis* 2012;23(6):74–368.
11. Baurand A, Eckly A, Hechler B. Differential regulation and relocalization of the platelet P2Y1 receptors after activation: a way to avoid loss of hemostatic properties? *Mol Pharmacol* 2005;67(3):721–733.
12. Bernardi B, Guidetti GF, Campus F. The small GTPase Rap1b regulates the cross talk between platelet integrin alpha2beta1 and integrin alphaIIb beta3. *Blood* 2006;107(7):35–2728.
13. Bird JE, Wang X, Smith PL. A platelet target for venous thrombosis? P2Y1 deletion or antagonism protects mice from vena cava thrombosis. *J Thromb Thrombolysis* 2012;34(2):199–207.
14. Bouman HJ, van Werkum JW, Rudez G. The influence of variation in the P2Y12 receptor gene on in vitro platelet inhibition with the direct P2Y12 antagonist cangrelor. *Thromb Haemost* 2010;103(2):86–379.
15. Cong Y, Liu X, Kang L, Yu Z. Pennogenin tetraglycoside stimulates secretion-dependent activation of rat platelets: evidence for critical roles of adenosine diphosphate receptor signal pathways. *Thromb Res* 2012;129(5):16–e209.
16. Dangelmaier C, Jin J, Smith JB. Potentiation of thromboxane A2-induced platelet secretion by Gi signaling through the phosphoinositide-3 kinase pathway. *Thromb Haemost* 2001;85:8–341.
17. Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. *J Clin Invest* 2004;113:5–340.

18. Garcia A, Kim S, Bhavaraju K. Role of phosphoinositide 3-kinase beta in platelet aggregation and thromboxane A2 generation mediated by Gi signalling pathways. *Biochem J* 2010;429(2):77–369.
19. Guidetti GF, Lova P, Bernardi B. The Gi-coupled P2Y12 Receptor Regulates Diacylglycerol-mediated Signaling in Human Platelets. *J Biological Chem* 2008;283(43):28795–28805.
20. Gratacap MP, Herault JP, Viala C. FcγRIIA requires a Gi-dependent pathway for an efficient stimulation of phosphoinositide 3-kinase, calcium mobilization, and platelet aggregation. *Blood* 2000;96(10):3439–3446.
21. Hardy AR, Conley PB, Luo J. P2Y1 and P2Y12 receptors for ADP desensitize by distinct kinase-dependent mechanisms. *Blood* 2005;105(9):3552–3560.
22. Hirsch E, Bosco O, Tropel P. Resistance to thromboembolism in PI3Kγ-deficient mice. *FASEB J* 2001;15(11):2019–2021.
23. Iyú D, Glenn JR, White AE. P2Y12 and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP. *Platelets* 2011;22(7):15–504.
24. Jin J, Quinton TM, Zhang J. Adenosine diphosphate (ADP)-induced thromboxane A(2) generation in human platelets requires coordinated signaling through integrin αIIbβ3 and ADP receptors. *Blood* 2002;99:8–193.
25. Jones S, Evans RJ, Mahaut-Smith MP. Extracellular Ca²⁺ modulates ADP-evoked aggregation through altered agonist degradation: implications for conditions used to study P2Y1 receptor activation. *Br J Haematol* 2011;153(1):83–91.
26. Judge HM, Buckland RJ, Sugidachi A. Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function. *Thromb Haemost* 2010;103(6):7–1210.
27. Kahner BN, Shankar H, Murugappan S. Nucleotide receptor signaling in platelets. *J Thromb Haemost* 2006;4(11):26–2317.
28. Kaplan ZS, Jackson SP. The role of platelets in atherothrombosis. *Hematology Am Soc Hematol Educ Program* 2011:51–61.
29. Kenneth A, Jacobson KA, Deflorian F, Costanzi S. Pharmacology of the platelet purinergic receptors. *Purinergic Signalling* 2011;7:305–324.
30. Kim S, Kunapuli SP. P2Y12 receptor in platelet activation. *Platelets* 2011;22(1):8–54.
31. Kim S, Jin J, Kunapuli SP. Akt activation in platelets depends on Gi signaling pathways. *J Biol Chem* 2004;279(6):95–4186.
32. Kim S, Jin J, Kunapuli SP. Relative contribution of G-protein-coupled pathways to protease-activated receptor-mediated Akt phosphorylation in platelets. *Blood* 2006;107(3):54–947.
33. Krajewski S, Kurz J, Geisler T. Combined Blockade of ADP Receptors and PI3-Kinase p110β Fully Prevents Platelet and Leukocyte Activation during Hypothermic Extracorporeal Circulation. *PLoS One* 2012;7(6):e38455.

34. Lee SJ, Kwon JA, Cho SA. Effects of testosterone and 17 β -oestradiol on expression of the G protein-coupled receptor P2Y₁₂ in megakaryocytic DAMI cells. *Platelets* 2012;23(8):579–85.
35. Li D, Wang Y, Zhang L, Luo X, Li J. Roles of Purinergic Receptor P2Y, G Protein-Coupled 12 in the Development of Atherosclerosis in Apolipoprotein E-Deficient Mice. *Arterioscler Thromb Vasc Biol* 2012;32(8):81–9.
36. Lombardi F, De Chaumont C, Shields DC, Moran N. Platelet signalling networks: pathway perturbation demonstrates differential sensitivity of ADP secretion and fibrinogen binding. *Platelets* 2012;23(1):17–25.
37. Loyau S, Dumont B, Ollivier V. Platelet glycoprotein VI dimerization, an active process inducing receptor competence, is an indicator of platelet reactivity. *Arterioscler Thromb Vasc Biol* 2012;32(3):85–778.
38. Manolopoulos P, Glenn JR, Fox SC. Acyl derivatives of coenzyme A inhibit platelet function via antagonism at P2Y₁ and P2Y₁₂ receptors: a new finding that may influence the design of anti-thrombotic agents. *Platelets* 2008;19(2):45–134.
39. Mendolicchio GL, Zavalloni D, Bacci M. Variable effect of P2Y₁₂ inhibition on platelet thrombus volume in flowing blood. *J Thromb Haemost* 2011;9(2):82–373.
40. Nieswandt B, Schulte V, Zywiec A. Costimulation of Gi- and G12/G13-mediated signaling pathways induces integrin α IIb β 3 activation in platelets. *J Biol Chem* 2002;277:8–39493.
41. Nisar SP, Cunningham M, Saxena K. Arrestin Scaffolds NHERF1 to the P2Y₁₂ Receptor to Regulate Receptor Internalization. *J Biol Chem* 2012;287(29):15–24505.
42. Noé L, Peeters K, Izzi B. Regulators of platelet cAMP levels: clinical and therapeutic implications. *Curr Med Chem* 2010;17(26):905–2897.
43. O'Brien KA, Stojanovic-Terpo A, Hay N. An important role for Akt3 in platelet activation and thrombosis. *Blood* 2011;118(15):23–4215.
44. Quinton TM, Murugappan S, Kim S. Different G protein-coupled signaling pathways are involved in alpha granule release from human platelets. *J Thromb Haemost* 2004;2:84–978.
45. Reiner S, Ziegler N, Leon C, Hoffmann C. beta-Arrestin-2 interaction and internalization of the human P2Y₁ receptor are dependent on C-terminal phosphorylation sites. *Mol Pharmacol* 2009;76(6):1162–71.
46. Risitano A, Beaulieu LM, Vitseva O. Platelets and platelet-like particles mediate intercellular RNA transfer. *Blood* 2012;119(26):95–6288.
47. Sage SO, Yamoah EH, Heemskerk JW. The roles of P2X₁ and P2T AC) receptors in ADP-evoked calcium signalling in human platelets. *Cell Calcium* 2000;28:26–119.
48. Saraf S, Wellsted D, Sharma S. Shear-induced global thrombosis test of native blood: pivotal role of ADP allows monitoring of P2Y₁₂ antagonist therapy. *Thromb Res* 2009;124(4):51–447.

49. Savi P, Zacharyus JL, Delesque-Touchard N. The active metabolite of Clopidogrel disrupts P2Y₁₂ receptor oligomers and partitions them out of lipid raft. *Proc Natl Acad Sci USA* 2006;103(29):11069–11074.
50. Shankar H, Garcia A, Prabhakar J. P2Y₁₂ receptor-mediated potentiation of thrombin-induced thromboxane A₂ generation in platelets occurs through regulation of Erk1/2 activation. *J Thromb Haemost* 2006;4:47–638.
51. Shanker J, Gasparyan AY, Kitis GD. Platelet function and antiplatelet therapy in cardiovascular disease: implications of genetic polymorphisms. *Curr Vasc Pharmacol* 2011;9(4):89–479.
52. Srinivasan S, Mir F, Huang JS. The P2Y₁₂ antagonists, 2-methylthioadenosine 5'-monophosphate triethylammonium salt and cangrelor (ARC69931MX), can inhibit human platelet aggregation through a Gi-independent increase in cAMP levels. *J Biol Chem* 2009;284(24):17–16108.
53. Stefanini L, Boulaftali Y, Ouellette TD. Rap1-Rac1 circuits potentiate platelet activation. *Arterioscler Thromb Vasc Biol* 2012;32(2):41–434.
54. Suzuki T, Obara Y, Moriya T. Functional interaction between purinergic receptors: effect of ligands for A_{2A} and P2Y₁₂ receptors on P2Y₁ receptor function. *FEBS Lett* 2011;585(24):84–3978.
55. Wu CC, Wu SY, Liao CY. The roles and mechanisms of PAR4 and P2Y₁₂/phosphatidylinositol 3-kinase pathway in maintaining thrombin-induced platelet aggregation. *Br J Pharmacol* 2010;161(3):58–643.
56. Young MT. P2X receptors: dawn of the post-structure era. *Trends Biochem Sci* 2010;35:83–90.
57. Zhong X, Kriz R, Seehra J. N-linked glycosylation of platelet P2Y₁₂ ADP receptor is essential for signal transduction but not for ligand binding or cell surface expression. *FEBS Lett* 2004;562(1):111–7.